Compare Sana Biotechnology Inc (SANA) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs VF Corp — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while VF Corp trades at $16.88 (market cap $6.62B). The key difference: VF Corp is far larger — about 7.6× Sana Biotechnology Inc's market cap, and VF Corp pays a 2.13% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | VFC | |
|---|---|---|
Market Cap | $873.84M | $6.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $21.55 |
52-Week Low | $2.68 | $11.66 |
Enterprise Value | $848.03M | $10.77B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
VFC trades at $16.91, down 0.41% with a bearish technical signal. The company shows mixed fundamentals with declining revenue from $11.8B in 2022 to $9.5B in 2025, though recent quarters beat EPS estimates. Net income turned negative in 2025 at -$190M, but 2026 projections show recovery to $255M profit. Valuation metrics appear reasonable with P/E of 26.38 and P/S of 0.7, while analyst consensus targets $19.33 with 43% buy ratings.
VFC faces turnaround challenges with weak Vans performance and consumer headwinds, but improving margins and debt reduction provide catalysts. The stock offers potential upside to analyst targets if brand recovery continues, though execution risks remain elevated given recent volatility and competitive pressures in apparel retail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
